In silico CD4 + T-cell multiepitope prediction and HLA distribution analysis for Marburg Virus—A strategy for vaccine designing

Dhasmana, Anupam; Dhasmana, Swati; Alsulimani, Ahmad; Kotnala, Sudhir; Kashyap, Vivek K.; Haque, Shafiul; Jaggi, Meena; Yallapu, Murali M.; Chauhan, Subhash C.

doi:10.1016/j.jksus.2021.101751

Cited by 1 publication

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reverse vaccinology or immunoinformatic (in silico only) studies of Marburg structural proteins have been recently published [ 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ]. The bulk of these studies limited their characterization of potential T cell epitopes to the envelope glycoproteins, VP 24 matrix protein, VP30 transcription factor, VP35 polymerase cofactor, and VP matrix protein of MARV [ 46 , 51 , 56 , 57 ].…”

Section: Resultsmentioning

confidence: 99%

“…Recently, the Marburg proteome was screened to identify potential immunogenic epitopes that bind to human MHC molecules. However, previous reports have focused solely on bioinformatics and in silico screening studies [ 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ] for human MHC molecules. Our contribution involves a bioinformatics analysis of potential immunogenic T cell epitopes specific to human MHC class I (i.e., HLA–A and B) and Cynomolgus MHC class I (Mafa MHC–A).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine

Harris,

Burkholz,

Herst

et al. 2024

Vaccines

View full text Add to dashboard Cite

The Marburg virus (MARV), the virus responsible for Marburg hemorrhagic fever (MHF), is considered a top-priority pathogen for vaccine development. Recent outbreaks in Equatorial Africa have highlighted the urgency of MARV because of its high fatality rate and historical concerns about potential weaponization. Currently, there are no licensed vaccines for MARV. Existing vaccine candidates rely on attenuated recombinant vesicular stomatitis virus carrying MARV glycoprotein (VSVΔG) or the chimpanzee replication-defective adenovirus 3 vector ChAd3-MARV. Although these platforms provide significant protection in animal models, they face challenges because of their limited thermal stability and the need for cold storage during deployment in resource-poor areas. An alternative approach involves using adjuvanted poly (lactic-co-glycolic acid) (PLGA) microparticles loaded with synthetic peptides representing MHC class I—restricted T cell epitopes. This vaccine platform has demonstrated effectiveness in protecting against SARS-CoV-2 and EBoV disease in animal models and has the advantage of not requiring cold storage and remaining stable at room temperature for over six months. This report outlines the design, manufacturing, and in vivo immunogenicity testing of PLGA microparticle human vaccines designed to prevent Marburg hemorrhagic fever.

show abstract